Short Interest in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Drops By 5.0%

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was the recipient of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 5,880,000 shares, a drop of 5.0% from the October 31st total of 6,190,000 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 374,500 shares, the days-to-cover ratio is presently 15.7 days.

Several institutional investors have recently made changes to their positions in LCTX. Defender Capital LLC. bought a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at approximately $3,709,000. Moors & Cabot Inc. bought a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at approximately $34,000. Rhumbline Advisers bought a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at approximately $177,000. Commonwealth Equity Services LLC bought a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at approximately $112,000. Finally, California Public Employees Retirement System bought a new stake in shares of Lineage Cell Therapeutics during the 3rd quarter valued at approximately $47,000.

LCTX stock opened at $0.82 on Tuesday. The firm has a 50-day moving average price of $0.98. Lineage Cell Therapeutics has a 12 month low of $0.66 and a 12 month high of $1.73.

LCTX has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $4.00 target price on shares of Lineage Cell Therapeutics in a report on Wednesday, November 13th. Chardan Capital reissued a “buy” rating on shares of Lineage Cell Therapeutics in a report on Thursday, August 22nd. Zacks Investment Research lowered shares of Lineage Cell Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 19th. Maxim Group set a $3.00 target price on shares of Lineage Cell Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, ValuEngine raised shares of Lineage Cell Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. Lineage Cell Therapeutics has a consensus rating of “Hold” and a consensus target price of $2.67.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Further Reading: Why is cost of goods sold important?

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.